1-(tert-butyl) 3-ethyl 3-(iodomethyl)piperidine-1,3-dicarboxylate | 948589-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(tert-butyl) 3-ethyl 3-(iodomethyl)piperidine-1,3-dicarboxylate
• 英文别名: 1-Tert-butyl 3-ethyl 3-(iodomethyl)piperidine-1,3-dicarboxylate；1-O-tert-butyl 3-O-ethyl 3-(iodomethyl)piperidine-1,3-dicarboxylate
• CAS: 948589-00-2
• 化学式: C₁₄H₂₄INO₄
• 分子量: 397.253
• InChiKey: DOMXASMASBMLJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  401.6±30.0 °C(Predicted)
• 密度：
  1.433±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(tert-butyl) 3-ethyl 3-(iodomethyl)piperidine-1,3-dicarboxylate 在 吡啶 、 4-二甲氨基吡啶 、 ammonium acetate 、 sodium methylate 、 potassium carbonate 、 一水合肼 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 14.5h， 生成 tert-butyl 2'-(2-chloropyridin-4-yl)-4'-oxo-5'-(2,4,6-trimethoxybenzyl)-1',4',5',6'-tetrahydro spiro[piperidine-3,7'-pyrrolo[3,2-c]pyridine]-1-carboxylate
  参考文献：
  名称：

  PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF

  摘要：

  Piperidin-ones compound of formula (I), the preparation method thereof, pharmaceutcal compositions comprising the compounds, and the pharmaceutical uses for the treatment of disorders are disclosed.

  公开号：

  WO2024125451A1
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 53.0h， 生成 1-(tert-butyl) 3-ethyl 3-(iodomethyl)piperidine-1,3-dicarboxylate
  参考文献：
  名称：

  Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors

  摘要：

  Structure-based methods were used to design P-sulfone 3,3-piperidine hydroxamates as TACE inhibitors with the aim of improving selectivity for TACE versus MMP-13. Several compounds in this series were synthesized and evaluated in enzymatic and cell-based assays. These analogs exhibit excellent in vitro potency against isolated TACE enzyme and show good selectivity for TACE over the related metalloproteases MMP-2, -13, and -14. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.022

文献信息

• [EN] MK2 INHIBITORS<br/>[FR] INHIBITEURS DE MK2
  申请人：ORGANON NV

  公开号：WO2011073119A1

  公开（公告）日：2011-06-23

  The present invention relates to compounds of general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used in the treatment of immune, autoimmune, inflammatory diseases, cardiovascular diseases, infectious diseases, bone resorption disorders, neurodegenerative diseases or proliferative diseases.

  本发明涉及一般式（I）的化合物或其药用盐。这些化合物可用于治疗免疫、自身免疫、炎症性疾病、心血管疾病、传染病、骨吸收障碍、神经退行性疾病或增殖性疾病。
• MK2 INHIBITORS
  申请人：Barf Tjeerd Andries

  公开号：US20120245175A1

  公开（公告）日：2012-09-27

  The present invention relates to compounds of general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used in the treatment of immune, autoimmune, inflammatory diseases, cardiovascular diseases, infectious diseases, bone resorption disorders, neurodegenerative diseases or proliferative diseases.

  本发明涉及一般式（I）的化合物或其药学上可接受的盐。这些化合物可用于治疗免疫、自身免疫、炎症性疾病、心血管疾病、传染病、骨吸收紊乱、神经退行性疾病或增殖性疾病。
• MK2 inhibitors
  申请人：Barf Tjeerd Andries

  公开号：US08772286B2

  公开（公告）日：2014-07-08

  The present invention relates to compounds of general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used in the treatment of immune, autoimmune, inflammatory diseases, cardiovascular diseases, infectious diseases, bone resorption disorders, neurodegenerative diseases or proliferative diseases.

  本发明涉及一般式（I）的化合物或其药学上可接受的盐。这些化合物可用于治疗免疫、自身免疫、炎症性疾病、心血管疾病、传染性疾病、骨吸收紊乱、神经退行性疾病或增生性疾病。
• ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS
  申请人：Wyeth Holdings Corporation

  公开号：EP1147085B1

  公开（公告）日：2005-11-16
• Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors
  作者：Allard Kaptein、Arthur Oubrie、Edwin de Zwart、Niels Hoogenboom、Joeri de Wit、Bas van de Kar、Maaike van Hoek、Gerard Vogel、Vera de Kimpe、Carsten Schultz-Fademrecht、Judith Borsboom、Mario van Zeeland、Judith Versteegh、Bert Kazemier、Jeroen de Roos、Frank Wijnands、John Dulos、Martin Jaeger、Paula Leandro-Garcia、Tjeerd Barf

  DOI：10.1016/j.bmcl.2011.04.016

  日期：2011.6

  The identification of a potent, selective, and orally available MK2 inhibitor series is described. The initial absence of oral bioavailability was successfully tackled by moving the basic nitrogen of the spiro-4-piperidyl moiety towards the electron-deficient pyrrolepyridinedione core, thereby reducing the pK(a) and improving Caco-2 permeability. The resulting racemic spiro-3-piperidyl analogues were separated by chiral preparative HPLC, and the activity towards MK2 inhibition was shown to reside mostly in the first eluting stereoisomer. This led to the identification of new MK2 inhibitors, such as (S)-23, with low nanomolar biochemical inhibition (EC(50) 7.4 nM) and submicromolar cellular target engagement activity (EC(50) 0.5 mu M). (C) 2011 Elsevier Ltd. All rights reserved.